replication
Latest
HIV-1 Matrix and Envelope Protein Interactions
It is important to characterize how HIV-1 proteins fulfill their functions in order to develop new approaches for curtailing the AIDS epidemic. One of the remaining frontiers of HIV-1 research concerns the mechanisms by which the HIV-1 matrix (MA) and envelope (Env) proteins collaborate with each other to ensure the assembly of infectious viruses. The HIV-1 MA protein directs the delivery of precursor Gag (PrGag) proteins to the plasma membranes (PMs) of infected cells, and drives the formation of lipid raft-like, liquid ordered (Lo) membrane domains. This membrane reorganization attracts a number of proteins that favor lipid raft-type microdomains. Such proteins appear to assemble into virus particles as innocent bystanders, and this appears to be how Env proteins that carry cytoplasmic tail deletions (CT) can be incorporated into virions. In contrast, wild type (WT) Env proteins additionally require an interaction with MA proteins to assemble into viruses. This is most easily understood in the context of the lattice that MA proteins construct at the PMs of infected cells. In particular, multiple lines of evidence imply that the CTs of WT Env proteins are trapped by MA lattices in immature, assembling virus particles, and then are released after assembled viruses are processed into their mature forms. Despite a seeming consensus on the MA-Env interaction steps, there are a number of very significant unknowns. Using our recent and preliminary results as a foundation, and taking advantage of the unique expertise of our collaborators, we propose the characterization of WT and mutant MA lattices, and of interactions of MA and Env with each other, and with membrane lipids. Our results will help clarify how MA and Env cooperate; they will illuminate aspects of host cell protein-membrane interactions; and they will foster the development of new approaches to intefere with HIV-1 replication.
Optimization of a novel and effective antiviral agent targeting Zika NS4B
This project focuses on developing novel anti-Zika virus (ZIKV) compounds targeting the NS4B protein, which is crucial for viral replication. ZIKV poses a significant medical challenge due to its potential for severe pathogenic outcomes, such as congenital Zika syndrome and Guillain-Barré Syndrome. Furthermore, its pandemic potential has been increasing with the expansion of carrier mosquito habitats. The project aims to address the urgent need for anti-ZIKV therapeutics that could greatly reduce severity of symptoms and minimize vertical and community transmissions. We have identified a novel small-molecule series with a benzamide scaffold through a cell-based, antiviral ultra-high-throughput screen. This series demonstrates strong potency against ZIKV without measurable cytotoxicity or non-specific antiviral effects, justifying this scaffold as a lead series for further development. Preliminary mechanism-of-action studies, utilizing genetic, biochemical, and virological assays, suggest that this series may inhibit the formation of the ZIKV viral replicase complex by interfering with NS4B. Our goal for this project is to develop a preclinical therapeutic candidate for ZIKV that demonstrates promising therapeutic activity following oral administration in ZIKV-infected mice, at a dosage that shows no clinical toxicity. The project has the following significant and novel objectives: 1) Optimize the benzamide lead for potency and drug-likeness; 2) Develop a lead candidate and a backup compound with optimized pharmacokinetic, pharmacodynamic, and toxicity profiles; 3) Determine the molecular mechanisms of action of the benzamide series using novel structural approaches to assist medicinal chemistry studies; 4) Evaluate the in vivo therapeutic efficacy and safety in mouse models and develop the best therapeutic regime. This project seeks to develop effective antivirals for ZIKV with high retention in the blood and central nervous system (CNS) and high oral bioavailability. The expected successful outcomes will provide significant advancements in ZIKV therapeutics and open new avenues for treating other flavivirus infections
TAR RNA binding to INI1/SMARCB1 and its role in HIV-1 transcription and latency reactivation
Abstract The goal of this application is to study the role of interplay between the components of chromatin remodeling SWI/SNF (BAF complex) and HIV-1 transcription machinery, focusing on the interaction of a BAF component, INI1 (Integrase Interactor 1) with TAR RNA. HIV-1 reservoirs are a mixture of latent cells harboring proviruses silenced at transcriptional level. Cure strategies need a deeper understanding of HIV-1 transcriptional regulation. HIV-1 transcription, initiated by RNA Pol II, pauses producing short TAR transcripts. pTEFb recruitment to TAR by Tat overcomes this transcriptional pause, facilitating elongation. Beyond Tat, the action of chromatin remodeling complexes (CRCs) is required to facilitate elongation. The BAF complexes CBAF and PBAF play distinct roles. While CBAF represses proviral transcription by maintaining nucleosomes in an unfavorable state, PBAF remodels nucleosomes to facilitate elongation. INI1 is a component of both CBAF and PBAF, and its role in transcription is not fully understood. INI1 was identified as a binding partner for HIV-1 integrase (IN) and exerts multifacted roles in virus assembly, production and morphogenesis. INI1 has multiple functional domains. IN binding Rpt1 domain structurally mimics TAR RNA & is necessary for late events. We have made a novel observation that another domain of INI1, the N-terminal Winged Helix DNA binding domain (WHD) specifically binds to TAR RNA and that this interaction is necessary for mediating HIV-1 transcriptional elongation. These exciting results suggest that different functional domains of INI1(Rpt1 and WHD) involved in “TAR RNA mimicry” or “TAR RNA binding” regulate distinct stages of replication. We hypothesize that INI1 WHD domain-TAR interaction is necessary for recruitment of PBAF to HIV-1 LTR for transcriptional elongation and latency reactivation. Disrupting this interaction results in transcriptional repression. We will investigate the role of this novel INI1:TAR RNA interaction in HIV-1 transcription and latency reactivation. This is a multi-PI application involving Drs. Kalpana (HIV-1 virologist), Heng (NMR biophysicist) and Zou (computational biologist/protein-RNA structure). In Aim 1, we will characterize INI1-WHD:TAR interaction in vitro and in vivo via molecular/genetic analyses (Kalpana/Heng). We will employ alanine scanning mutagenesis based on WHD NMR structure to test WHD:TAR interaction. We will use biophysical & biochemical approaches to probe TAR structural elements required for this interaction. In Aim 2, we will employ computational modeling and NMR to determine the structure of INI1- WHD:TAR RNA complex (Zou/Heng). In Aim 3, we will determine the role of INI1:TAR interactions in HIV-1 transcription, latency reactivation and mechanism of action (Kalpana). We will analyze the effect of TAR- Interaction-Defective (TID) INI1 mutants on transcription of LTR-reporters and full-length HIV in INI1-/- cells. Latent cells in which TID-INI1 mutants are knocked in (KI) will be used to assess effect on reactivation via RNA-FISH and qRT-PCR assays. Our studies will establish INI1:TAR interaction as a drug target. Inhibiting this interaction could block latency reactivation promoting deep latency and advancing cure strategies.
Neutralizing persistent IFN-I to improve HIV-specific CAR T cell therapy
PROJECT SUMMARY A critical hurdle to further improving the quality of life for people living with HIV (PLWH) is the need to resolve the residual immune activation and inflammation that persists even in those taking effective antiretroviral therapy (ART), which suppresses HIV replication. This unresolved and persistent immune activation is associated with increased type-I interferon (IFN-I) signaling, and increased incidence of comorbidities. Encouragingly, reports demonstrate that blocking IFN-I signaling in animal models of HIV infection can reduce HIV reservoirs and restore T cell immune function. We hypothesize that blocking IFN-I would likewise augment engineered T cell-based therapies against HIV, such as chimeric antigen receptor (CAR) T cells. Our prior work has demonstrated that when engineered to express both the 4-1BB and CD28 costimulatory domains and protected from HIV infection, HIV-specific CD4 ectodomain CAR T cells can reduce acute viremia, prevent CD4+ T cell loss, and reduce viral burden in the tissues of HIV-infected humanized mice. However, the reduction of plasma viral loads was ultimately transient, suggesting that the potency of HIV-specific CAR T cells should be further optimized for clinical translation. Our preliminary data highlights interferon-beta (IFNb) as a key immunosuppressive IFN-I negatively regulating CAR T cell proliferation, and we demonstrate that neutralizing IFNb in vivo enhanced the engraftment and persistence of HIV-specific CAR T cells adoptively transferred into HIV-infected ART- suppressed humanized mice. This proposal will interrogate whether IFNb neutralization augments CAR T cell therapy through 1) identifying the mechanism(s) by which chronic IFNb exposure mediates HIV-specific CAR T cell dysfunction, and 2) determining the effect of neutralizing IFNb on CAR T cell function and persistence in HIV infection in vivo. The proposed aims seek to develop the neutralization of IFNb as a novel immunotherapy approach to maximize the potency of HIV-specific CAR T cells aimed at achieving a functional HIV cure.
Continued HIV Production From Infected Macrophage In People On ART
PROJECT ABSTRACT After a few weeks of antiretroviral therapy (ART), HIV-1 RNA often decays to undetectable levels in blood. The initial decay is typically rapid due to the loss of short-lived, HIV-infected CD4+ T cells, but despite being adherent to ART, some people experience a subsequent period of slower decay and may require months to years to reach virologic suppression. The clinical significance of ‘slow decay’ of HIV-1 RNA after starting ART is currently unknown. Assessing the clinical significance of ‘slow decay virus’ requires identify the mechanisms generating it and exploring whether there is ongoing inflammation and neuronal damage in these people. There are three potential mechanisms that may generate ‘slow decay virus’ and they may have very different clinical implications. (1) Continued HIV-1 replication due to ineffective ART, poor ART adherence or drug- resistance. (2) Alternatively, ART could stop HIV-1 replication, but HIV-1 virions may continue to be produced by HIV-infected CD4+ T cells or (3) macrophage. Virus production without replication that emerges at the time of ART initiation is called primary nonsuppresible viremia (NSV) and is mechanistically distinct from secondary NSV observed in people who were previously suppressed. We recently examined four people who required approximately a year to become suppressed and found that ART stopped HIV-1 replication, but HIV-infected macrophage continued to produce substantial amounts of virus. These preliminary results are consistent with the long-held belief that after starting ART there is a period of rapid viral decay due to loss of HIV-infected CD4+ T cells, but some people have a subsequent period of slower decay due to continued virus production from long- lived, HIV-infected macrophage. The proposed work will expand on these observations and examine the mechanisms generating ‘slow decay virus’ in a much larger cohort of people on ART and explore the clinical implications of having ‘slow decay virus’ after starting ART (i.e. primary NSV). We will use existing, archived, longitudinal blood samples from 99 people in the MACS/WIHS Combined Cohort Study (MWCCS) who did not suppress HIV-1 RNA to undetectable levels by 6 months on ART (i.e. people with ‘slow decay virus’) and samples from 30 people who suppressed virus with typical, rapid kinetics. The proposed experiments will identify the mechanisms generating ‘slow decay virus’ during ART and the clinical implications of ‘slow decay virus’ (Aim 1). In our previous study, we also observed that ‘slow decay virus’ produced by macrophage often had nonsense/frameshift mutations in the HIV-1 vpr gene that may have promoted continued HIV-1 production from macrophage during ART. Specifically, we will explore whether ‘slow decay virus’ populations produced by macrophage have mutations in vpr or other genes that impact macrophage survival and/or HIV-1 production from infected macrophage (Aim 2). We will accomplish these aims using cutting-edge, but highly rigorous approaches. Accomplishing these aims will address clinical concerns about ‘slow decay virus’, the source of ‘slow decay virus’ as well as the role that Vpr plays in HIV-1 persistence and expression in macrophage during ART.
The multiciliation cycle: a variant cell cycle coordinating centriole biogenesis and ciliogenesis
Project summary/Abstract Differentiating multiciliated cells line the mammalian airway and are critical for protecting the lungs from inhaled pathogens and particulates. Multiciliated cells have a distinct architecture from other cell types, having hundreds of centrioles, each of which matures into a basal body and nucleates a motile cilium. Defects in multiciliation cause a form of Primary Ciliary Dyskinesia (PCD), a lung disease. Most cells generate two centrioles and one cilium per cell cycle. We found that differentiating multiciliated cells redeploy cell cycle regulators into a novel cell cycle variant, which we refer to as the multiciliation cycle, to break these rules, generate hundreds of centrioles and cilia, and coordinate their differentiation. The multiciliation cycle redeploys many mitotic cell cycle regulators, including cyclin-dependent kinases (CDKs) and their cognate cyclins. For example, Cyclin D1-CDK4/6, regulators of mitotic G1 to S progression, is required for multiciliated cell fate initiation and entry into the multiciliation cycle. While we have focused on lung multiciliated cells, others have found that cell cycle regulators similarly participate in multiciliation of ependymal cells of the brain. Some cells, such as mammalian trophoblast giant cells, employ cell cycle variants like the endocycle to bypass mitosis. We propose that the multiciliation cycle is another cell cycle variant that augments some aspects of the canonical cell cycle, such as centriole synthesis, and blocks others, such as DNA replication. During the multiciliation cycle, E2F7, a transcriptional regulator of canonical S to G2 progression, is expressed at high levels. During multiciliated cell differentiation, E2F7 directly dampens expression of genes encoding DNA replication machinery and terminates the S phase-like gene expression program. Loss of E2F7 causes a reacquisition of DNA synthesis in multiciliated cells and dysregulation of multiciliation cycle progression, disrupting centriole maturation and ciliogenesis. We propose that multiciliated cell differentiation is coordinated by an alternative cell cycle that organizes, instead of cell proliferation, the steps of cell differentiation. In this project, we investigate how the multiciliation cycle redeploys the mitotic cell cycle regulatory framework to generate many centrioles without undergoing DNA synthesis or cytokinesis. More specifically, we seek to uncover how CDKs and cyclins are regulated to control the amount and timing of basal body synthesis, how Retinoblastoma (RB) protein controls the transcriptional program of multiciliation, and how E2Fs advance the multiciliation cycle. This work will test the hypothesis that multiciliation is organized by a variant cell cycle that uncouples centriole synthesis from DNA replication and mitosis. We propose that his variant cell cycle orchestrates progression through sequential phases required to construct the multiciliated cells that protect the lungs.
Fidelity and Replication: Modelling the Impact of Protocol Deviations on Effect Size
Cognitive science and cognitive neuroscience researchers have agreed that the replication of findings is important for establishing which ideas (or theories) are integral to the study of cognition across the lifespan. Recently, high-profile papers have called into question findings that were once thought to be unassailable. Much attention has been paid to how p-hacking, publication bias, and sample size are responsible for failed replications. However, much less attention has been paid to the fidelity by which researchers enact study protocols. Researchers conducting education or clinical trials are aware of the importance in fidelity – or the extent to which the protocols are delivered in the same way across participants. Nevertheless, this idea has not been applied to cognitive contexts. This seminar discusses factors that impact the replicability of findings alongside recent models suggesting that even small fidelity deviations have real impacts on the data collected.
Feasibility of the Pavlovian instrumental transfer task using a full transfer paradigm: A replication and meta-analysis
FENS Forum 2024
Spontaneous EEG correlates of visual exploration phenotypes: A replication study
FENS Forum 2024
replication coverage
9 items
Add content
Have a seminar, talk, or paper on replication? Post it so others working in this area can find it.
Post content